Predictors of tumour response to neoadjuvant chemotherapy in resected PDACs

Pancreatic ductal adenocarcinoma PDAC is amongst the most lethal solid tumors. Curative treatment, Surgery along with chemotherapy, is feasible in only about 15% of cases since majority of the PDACs are metastatic or locally advanced at presentation. Despite the surgical advancements made in the past few years, multidisciplinary management with neo-adjuvant modalities hold the key for further improving the outcomes for PDAC. Neoadjuvant therapy holds potential in improving rate of margin negative resections R0 and allows for testing tumour biology for selecting patients who will benefit most from major pancreatic resections. In the context of PDAC though evidence is fast building up, there is still a lack of consensus on factors predicting response after neo-adjuvant therapy and in turn its effect on long-term survival. Therefore, it is essential to conduct a multicenter international study to better understand the prognostic factors for long-termsurvival in this group of patients.

In this multicenter retrospectivestudy,group of hospitals performing pancreatic surgery will participate by providing data on all the relevant preoperative, operative, and postoperative variables of patients undergoing pancreatectomy for PDAC. In the data collection we will collect information like age, medical history, neo-adjuvant therapy, surgery etc. Patients operated between 2015 and 2023 will be included. Our main goal is identify factors predicting response to neo-adjuvant therapy and its co-relation to survival.